Julie Shilane's Archive

Julie joined Light Knowledge Resources in March of 2008 after graduating from Princeton University with her Ph.D. in Chemistry. Her dissertation research involved the development of small molecule chemotherapeutics. She also has a B.S. in Chemistry and Mathematics from Moravian College. At LKR, Julie works on the development of the Beacon websites. With several family members who have battled cancer, she aspires to help patients through her work at The Beacon. Julie's interests include crafts, playing piano, and spending time with her family.

Julie Shilane has written 86 article(s) .

[ by | Jul 23, 2009 2:02 pm | Comments Off ]
Beacon BreakingNews - Clinical Trial Supports Revlimid As First-Line Therapy For Myeloma

Celgene, the manufacturer of Revlimid (lenalidomide), announced today positive results from a Phase 3 clinical trial using Revlimid as first-line therapy for newly diagnosed multiple myeloma patients. Results show that Revlimid in combination with melphalan (Alkeran) and prednisone, followed by continuous Revlimid, significantly improved time to tumor progression.

Check back for further coverage on The Myeloma Beacon.

Update: Please see The Myeloma Beacon's full coverage of Revlimid as a first-line therapy for myeloma.

Tags: , ,
Read the full story »
[ by and | Jan 6, 2009 5:54 pm | Comments Off ]

The health care system in the United Kingdom is making more treatment options available to terminally ill patients.

In England and Wales, the National Institute for Health and Clinical Excellence (NICE) decides which treatments will be made available under the state-funded National Health Service.  Until recently, NICE refused to approve the use of any drug costing more than £30,000 ($44,000) for each extra year of good health attributable to the drug.

On January 2, NICE issued new guidelines to approve, …

Tags: , ,
Read the full story »